Steven Pearson, ICER president (Jeff Rumans)
ICER panel says two ALS drug candidates have 'low' long-term value
ALS is well-known as one of the most difficult drug targets, and the US cost-effectiveness watchdog ICER isn’t quite inching closer to endorsing the two …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
